SYA16263

01/01/2021 - "Furthermore, we have demonstrated SYA16263 (5) is functionally selective and produces antipsychotic-like behavior but without inducing catalepsy in rats. "
01/01/2019 - "When tested in animal behavior tests for catalepsy, SYA16263 did not produce catalepsy at doses up to 19 times the apomorphine ED50 value predicting little or no extra-pyramidal (EPS) side effects in humans. "
01/01/2019 - "Evaluation of SYA16263 as a new potential antipsychotic agent without catalepsy."
03/15/2021 - "We have also more recently reported that SYA16263 has antipsychotic-like properties with an absence of catalepsy in animal models ascribed to its ability to recruit β-arrestin to the D2 receptor. "
01/01/2019 - "Functional activities for SYA16263 show that it acts as a D2 agonist at both the Gi and β-arrestin pathways, similar to, but better than aripiprazole, which could account for the absence of the catalepsy observed. "